News

Article

FDA approves Eyenovia’s Redwood City commercial manufacturing facility

Author(s):

According to a news release, the Redwood City, California, site will complement Eyenovia’s facility in Reno, Nevada as well as its contract manufacturer, Coastline International, to produce commercial supply of Mydcombi.

(Image Credit: AdobeStock/Gorodenkoff)

(Image Credit: AdobeStock/Gorodenkoff)

Eyenovia Inc announced its facility in Redwood City, California successfully completed FDA inspection for approval as a commercial manufacturing facility.

According to a news release from Eyenovia,1 its Redwood City facility will primarily be used for final assembly, packaging, and labeling activities in support of Mydcombi, the first and only fixed combination of tropicamide and phenylephrine for in-office and pre-surgical pupil dilation utilizing Optejet technology.

Michael Rowe, Eyenovia’s CEO, pointed out in the news release the inspection went off without a hitch.

“The FDA inspection of our Redwood City facility was completed efficiently and with no significant concerns raised on the part of the inspector, clearing the way for us to perform final assembly, packaging and labeling in support of a broader U.S. launch of Mydcombi,” Rowe said in the news release. “With Redwood City and Reno now online and operational, we have the capacity to manufacture both commercial product as well as clinical supply in support of our ongoing CHAPERONE clinical trial for pediatric progressive myopia as well as initial testing of other product candidates that leverage our Optejet technology.”

Moreover, Eyenovia noted in its news release the Redwood City site complements its manufacturing capabilities in Reno, as well as its contract manufacturer, Coastline International, to produce commercial supply of Mydcombi in the company’s proprietary Optejet dispensing platform.

“I am very pleased with the results of the audit and commend our manufacturing, engineering, quality and regulatory staff for their diligence and work to make this a reality,” Bren Kern, the company’s COO, added in the news release. “The team had been working tirelessly in preparation for this key milestone and their efforts bore out in the result.”

Reference:
  1. Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility | Eyenovia Inc. Eyenovia Inc. Published 2024. Accessed February 13, 2024. https://ir.eyenovia.com/news-releases/news-release-details/eyenovia-announces-fda-approval-redwood-city-commercial

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
© 2025 MJH Life Sciences

All rights reserved.